

Nouveau Biosciences and University of Virginia (UVA) Announce Second Licensing Agreement to Expand the Company's Unique Pipeline of Innovative Nanomedicines

[New York, NY – February, 10, 2026] – Nouveau Biosciences, a biotechnology company pioneering nanomedicines and targeted drug delivery to improve cancer therapeutics, today announced that it has executed a second Licensing Agreement with the University of Virginia (UVA) to expand the company's pipeline.

The Licensing Agreement ratifies Nouveau's rights to six additional novel nanomedicine assets, broadening the company's development opportunities across solid tumor oncology and immunomodulatory indications. These programs are being developed as potential adjunctive therapies, including in combination with immune checkpoint inhibitors and CAR T cell therapies, addressing areas of high unmet medical need.

"This second licensing agreement strengthens our pipeline in a meaningful way, and reinforces the strategic depth of our platform," said Owen A. O'Connor, M.D., Ph.D., Founder, Chief Executive Officer, and Chairman of Nouveau Biosciences. "By leveraging our proprietary Nouveau Nexus™ discovery platform and its versatile amphiphilic block copolymer chemistry, we are building a portfolio of differentiated nanomedicines designed to improve both the safety and effectiveness of cancer therapies across multiple disease settings."

The company's Nouveau Nexus™ platform integrates advanced polymer chemistry with rational drug design to enable the development of tailored nanomedicines and combinatorial therapeutics. The newly licensed assets further validate the platform's ability to generate IP-protected, clinically relevant drug candidates with broad applicability.

The chemistry underlying the Nouveau Nexus™ platform provides an exceptionally flexible framework for designing nanomedicines optimized for distinct molecular features of cancer," said Chuck Karan, Ph.D., Chief Scientific Officer of Nouveau Biosciences. "This level of tunability allows us to systematically tailor therapeutic performance in a way that is rarely achievable with conventional drug development approaches."

One of the newly licensed assets has already attracted external validation and is the subject of a previously announced Memorandum of Understanding with **CanceRx**, a purpose-driven funding and development platform focused on advancing innovative oncology treatments through long-duration capital and strategic partnerships.

Further details regarding the newly licensed assets and development plans will be announced as programs advance toward translational and clinical development.

About Nouveau Biosciences

Nouveau Biosciences is an innovative biotechnology company that deploys a proprietary platform technology, the *Nouveau Nexus*[™], that integrates the latest scientific advances in cancer biology, genomics, computational biology and nanomedicine to produce precision targeted drugs tailored for very specific types of cancer. Its polymer-based nanoparticles are engineered to deliver both individual drugs and optimized combinations with enhanced precision, leading to improved tolerability and efficacy. The company's lead programs are clinic-ready, backed by strong intellectual property, and designed to address high-need oncology indications. The technology represents a quantum advance in the generation of highly precision targeted drugs, offering innumerable advances over technologies.

About CanceRx

CanceRx is a nonprofit and investment platform designed to support the development of promising cancer drugs through long-duration funding, clinical guidance, and FDA submission support. The organization partners with scientific innovators to bring life-changing oncology therapies to patients, and works closely with pharmaceutical companies to license and scale validated assets. Learn more at <https://cancerx.us>.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the companies' future plans, development and licensing of cancer therapeutics, and the potential success of the collaboration. All statements other than statements of historical fact are forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements. Nouveau Biosciences undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by law.

Media Contact

Petrina Whyte

media@nouveaubiosciences.com